BRCA2-RAD51-IN-3
BRCA2-RAD51-IN-3 is a RAD51-BRCA2 protein-protein interaction inhibitor with an EC50 of 29.35 μM and a Kd of 75.14 μM. BRCA2-RAD51-IN-3 blocks RAD51-BRCA2 binding, impairs homologous recombination in cancer cells, and induces synthetic lethality. BRCA2-RAD51-IN-3 acts in human pancreatic cancer cells and shows no activity in normal pancreatic cells. BRCA2-RAD51-IN-3 can be used for the research of pancreatic cancer.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Formule: C21H14NNaO4
- Masse moléculaire:367.33
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Activité biologique
Description
In Vitro
BRCA2-RAD51-IN-3 (compound 19) inhibits the RAD51-BRCA2 protein-protein interaction in an in vitro ELISA assay with a EC50 of 29.35 μM and a maximum inhibition of 76%[1].
BRCA2-RAD51-IN-3 binds directly to recombinant human RAD51 with a Kd of 75.14 μM, as measured by MST[1].
BRCA2-RAD51-IN-3 (50 μM; 1 μM RAD51 plus 2-5 μM BRC4 peptide) binds to the RAD51-BRCA2 interaction interface, as confirmed by NMR displacement assays[1].
BRCA2-RAD51-IN-3 (10-80 μM) dose-dependently inhibits homologous recombination in BxPC-3 cells with an IC50 of 21.74 μM, reaching 81% inhibition at 80 μM[1].
BRCA2-RAD51-IN-3 (10-60 μM) inhibits homologous recombination in HEK-293 cells, reducing HR-proficient cells at 40 μM[1].
BRCA2-RAD51-IN-3 disrupts RAD51 foci formation in BxPC-3 cells after Cisplatin (HY-17394)-induced DNA damage, consistent with inhibition of RAD51-BRCA2-mediated DNA repair[1].
BRCA2-RAD51-IN-3 (40 μM; 6 days, in combination with 10 μM Olaparib (HY-10162) ) reduced cell viability synergistically in 2D BxPC-3 and HPAC cells (Interaction Index = 0.77 and 0.72, respectively), had no significant effect on the viability of normal H-6037 pancreatic epithelial cells, and induced apoptosis in BxPC-3 and HPAC cells as evidenced by a significantly increased BAX/BCL2 ratio.
BRCA2-RAD51-IN-3 (40-60 μM; 144 hours, in combination with 10 μM Olaparib) synergizes with Olaparib to reduce viability, inhibit growth, and induce cell death in BxPC-3 3D spheroids, with a 3D Interaction Index of 0.85 after 144 hours of treatment[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:BxPC-3 human pancreatic adenocarcinoma cells (2D culture)
-
Concentration:40 μM (in combination with 10 μM olaparib)
-
Incubation Time:6 days
-
Result:Had no significant effect on cell viability; in combination with olaparib, significantly enhanced antiproliferative activity with an Interaction Index of 0.77, indicating synergism.
-
Cell Line:HPAC human pancreatic adenocarcinoma cells (2D culture)
-
Concentration:40 μM (in combination with 10 μM olaparib)
-
Incubation Time:6 days
-
Result:Had no significant effect on cell viability; in combination with olaparib, significantly enhanced antiproliferative activity with an Interaction Index of 0.72, indicating synergism.
-
Cell Line:H-6037 normal human pancreatic epithelial cells (2D culture)
-
Concentration:40 μM (in combination with 10 μM olaparib)
-
Incubation Time:6 days
-
Result:The combination had no significant effect on cell viability.
-
Cell Line:BxPC-3 human pancreatic adenocarcinoma cells (3D spheroid culture)
-
Concentration:40-60 μM (in combination with 10 μM olaparib)
-
Incubation Time:6 days
-
Result:Had no significant effect on spheroid viability or volume; in combination with olaparib, 60 μM significantly reduced spheroid viability and volume, and increased cell death, with a 3D Interaction Index of 0.85, indicating synergism.
-
Cell Line:BxPC-3 and HPAC human pancreatic adenocarcinoma cells
-
Concentration:40 μM (in combination with 10 μM olaparib)
-
Incubation Time:6 days
-
Result:Significantly increased the BAX/BCL2 ratio in both cell lines, indicating induction of apoptotic cell death.
Chemical Information
-
Masse moléculaire 367.33
-
Formule C21H14NNaO4
-
SMILES
O=C(C1=CC(C2=CC=C(C3=CC=CC=C3)O2)=NC4=CC=C(OC)C=C14)O[Na]
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocole
-
CRISPR-Cas9 HDR knock-in/precise editing
CRISPR-Cas9 HDR knock-in uses a guide RNA to direct Cas9 to a genomic target adjacent to a PAM, where Cas9 creates a double-strand break; if a donor DNA template with homology to the cut region is present, cellular HDR can copy the donor sequence into the genome, producing a precise substitution, tag, reporter, or insertion rather than an indel. The readout is the fraction of alleles or cells carrying the intended donor-derived edit, measured by junction PCR, restriction-fragment analysis, Sanger sequencing, amplicon deep sequencing, flow cytometry for reporter knock-in, or clone genotyping; NHEJ indels and partial or non-HDR insertions are measured in parallel because they compete with or confound precise HDR outcomes.
-
Pull-down
The pull-down assay is an in vitro technique used to detect physical interactions between two or more proteins and an invaluable tool for confirming a predicted protein-protein interaction or identifying novel interacting partners. This method typically involves the use of affinity purification with various wash and elution steps.
-
Immunoprecipitation
Immunoprecipitation (IP) is an experimental method that uses the principle of antibody specific binding to purify and enrich target proteins.
-
Protocol for Bimolecular Fluorescence Complementation (BiFC) Assay
Bimolecular fluorescence complementation detects protein-protein proximity in living or fixed cells by fusing two candidate interaction partners to nonfluorescent N- and C-terminal fragments of a fluorescent protein; when the partners interact or remain close enough, the fluorescent fragments complement, mature, and generate a fluorescent signal at the site of the protein complex. The BiFC readout is fluorescence intensity and subcellular localization of the reconstituted fluorophore, which reflects formation or stabilization of a protein complex rather than direct biochemical binding kinetics; BiFC is therefore useful for mapping where interactions occur in cancer cells, neurons, macrophages, organoid-derived cells, or drug-screening systems, but results should be validated by independent assays such as co-IP or Western blot. BiFC signal formation is delayed by fluorophore maturation and can stabilize otherwise transient complexes, so it is not a real-time reversible interaction assay
-
Co-Immunoprecipitation
Co-immunoprecipitation technology can verify protein interaction based on the specific immune reaction between antibodies and antigens.
-
Protocol for Yeast Two-Hybrid (Y2H) Assay
The yeast two-hybrid assay detects binary protein-protein interactions by separating a transcription factor into a DNA-binding domain fused to a "bait" protein and a transcriptional activation domain fused to a "prey" protein; if bait and prey interact in yeast, the transcription factor is reconstituted and activates reporter genes such as HIS3, ADE2, lacZ, MEL1, or other selectable/readable reporters. The readout is yeast growth on selective medium and/or reporter activity, which reflects proximity-dependent transcriptional activation in the yeast nucleus rather than direct biochemical binding in the original mammalian, tumor, neuronal, macrophage, or organoid context. Because yeast two-hybrid can generate false positives and false negatives, interaction claims should be validated using independent assays such as co-immunoprecipitation, Western blot, immunofluorescence colocalization, BiFC, pull-down, or mammalian two-hybrid assays.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)